Skip to main content
placeholder image

Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome

Journal Article


Abstract


  • Anamorelin hydrochloride is an orally active ghrelin receptor agonist in development by Helsinn, for the treatment of non-small-cell lung cancer (NSCLC) cachexia. In preclinical and clinical studies, the potent affinity of anamorelin for the ghrelin receptor is associated with significant appetite-enhancing activity and resultant improvements in body weight, lean body mass, and handgrip strength compared with placebo. The accompanying stimulatory effects on growth hormone and IGF-1 are not associated with tumor growth, and overall survival in patients with cancer is not compromised. Anamorelin is well tolerated with no dose-limiting toxicities identified to date. The findings of ongoing Phase III studies are needed to confirm the significant potential of anamorelin to treat NSCLC cachexia. �� 2014 Future Medicine Ltd.

Publication Date


  • 2014

Citation


  • Currow, D. C., & Abernethy, A. P. (2014). Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome. Future Oncology, 10(5), 789-802. doi:10.2217/fon.14.14

Scopus Eid


  • 2-s2.0-84899854738

Start Page


  • 789

End Page


  • 802

Volume


  • 10

Issue


  • 5

Place Of Publication


Abstract


  • Anamorelin hydrochloride is an orally active ghrelin receptor agonist in development by Helsinn, for the treatment of non-small-cell lung cancer (NSCLC) cachexia. In preclinical and clinical studies, the potent affinity of anamorelin for the ghrelin receptor is associated with significant appetite-enhancing activity and resultant improvements in body weight, lean body mass, and handgrip strength compared with placebo. The accompanying stimulatory effects on growth hormone and IGF-1 are not associated with tumor growth, and overall survival in patients with cancer is not compromised. Anamorelin is well tolerated with no dose-limiting toxicities identified to date. The findings of ongoing Phase III studies are needed to confirm the significant potential of anamorelin to treat NSCLC cachexia. �� 2014 Future Medicine Ltd.

Publication Date


  • 2014

Citation


  • Currow, D. C., & Abernethy, A. P. (2014). Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome. Future Oncology, 10(5), 789-802. doi:10.2217/fon.14.14

Scopus Eid


  • 2-s2.0-84899854738

Start Page


  • 789

End Page


  • 802

Volume


  • 10

Issue


  • 5

Place Of Publication